Here we found that tamoxifen promotes multiple changes in PSCs and the microenvironment of pancreatic cancer through a GPER‐dependent mechanism that induces a negative regulation of HIF‐1A by decreasing actomyosin‐dependent PSC contractility and matrix stiffness mechanosensing (Fig 8). The gene discussed is HIF1A; the disease is pancreatic neoplasm.